13014_2016_657_MOESM2_ESM.odp (16.89 kB)

Additional file 2: Figure S1. of Carbon ion therapy (C12) for high-grade malignant salivary gland tumors (MSGTs) of the head and neck: do non-ACCs profit from dose escalation?

dataset

posted on 2016-07-07, 05:00 authored by A. Jensen, M. Poulakis, V. Vanoni, M. Uhl, N. Chaudhri, P. Federspil, K. Freier, J. Krauss, J. Debus

PFS according to histologic subtype. AC: adenocarcinoma; ACI: acinic cell carcinoma; MEC: mucoepidermoid carcinoma. Note only the most frequent subtypes are shown to improve visibility (ODP 16 kb)

Funding

Deutsche Forschungsgemeinschaft (DFG)

History

Usage metrics

Keywords

mucoepidermoid carcinoma Additional ACI histologic subtype gland tumors non-ACCs profit Carbon ion therapy dose escalation adenocarcinoma MEC MSGT ODP 16 kb visibility acinic cell carcinoma Figure PFS 1.

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM